Propanc Registers 6.5M Shares for Hexstone Resale — 66% Potential Dilution
PPCB is trading near its 52-week low of $0.471 (6.1% above the low).
Summary
Propanc Biopharma registered 6.5 million shares for resale by Hexstone Capital, a Series C Preferred holder. If fully sold, outstanding shares would rise 66% from 9.8M to 16.3M, with the company receiving no proceeds.
Key Events · Financing and Capital Events · PPCB
-
6.5M Share Resale Registration
The S-1 registers 6.5 million shares for resale by Hexstone Capital, up from 2.5 million in the July 17, 2026 filing. The company receives no proceeds.
-
66% Potential Dilution
If all registered shares are sold, shares outstanding would rise from 9,831,116 to 16,331,116 — a 66% increase.
-
Conversion Floor Reset to $0.05
After the May 2026 reverse split, the Series C Preferred conversion floor price was reduced to $0.05, enabling deeply discounted conversions.
-
Warrant Overhang of $99M
Hexstone holds warrants to purchase up to 9,400 additional Series C Preferred shares at $10,000 each, representing up to $99M in potential additional proceeds if exercised.
Analysis · PPCB · Life Sciences
A new S-1 from Propanc Biopharma registers 6.5 million shares for resale by Hexstone Capital, the holder of Series C Preferred Stock and warrants. The company will receive no proceeds from these resales. If all 6.5 million shares are sold, shares outstanding would rise from 9,831,116 to 16,331,116 — a 66% increase. The Series C conversion floor price has been reset to just $0.05 after the May 2026 reverse split, meaning Hexstone can convert at deeply discounted prices and sell into the market. This comes on top of a going-concern warning, material weaknesses, and an $18.9M net loss disclosed in the September 25, 2026 10-K. The registration makes a large overhang tradable at a time when the company is already under severe financial stress.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPCB was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.47 to $52.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.